Tempest Therapeutics (TPST) Income from Non-Controlling Interests (2018)
Tempest Therapeutics (TPST) posted Income from Non-Controlling Interests of $691000.0 for Q4 2018, up 294.65% sequentially from -$355000.0 in Q3 2018.
Tempest Therapeutics (TPST) Income from Non-Controlling Interests (2018) Analysis & Trends
Tempest Therapeutics has reported Income from Non-Controlling Interests for 1 years, with the latest figure at $691000.0 in Q4 2018.
- Quarterly Income from Non-Controlling Interests changed N/A year-over-year to $691000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $15000.0 (changed N/A YoY) and the FY2018 annual result came in at $15000.0, up 287.5% from the prior year.
- Income from Non-Controlling Interests improved to $691000.0 in Q4 2018 per TPST's latest filing, from -$355000.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $691000.0 in Q4 2018 and troughed at -$355000.0 in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Tempest Therapeutics | 4.32 Mn | 3.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 691,000.00 |
| Sep 30, 2018 | -355,000.00 |
| Jun 30, 2018 | -196,000.00 |
| Mar 31, 2018 | -125,000.00 |